No. of Recommendations: 1
So yes, Clinical drug trials involve a LOT of recruiting of various populations and subpopulations, and even having recruitment quotas in order to satisfy the statistical wonks who will reject a protocol if a particular study population is too small to provide a statistically significant conclusion. - Bill
---------------
Fine with me, recruit all the biological males and biological females you need for your study. Who they sleep with should not be factor and maybe it isn't in the cancer research wing of the NIH. Males and Females, you said it yourself right here,
"How do they determine proper dosages for males v females? Or even if females or males can safely take a drug, or even whether or not the drug is effective?"
So your conclusion is to stop looking. My desire is to keep looking not solely for DEI but for any apparent waste or abuse that then can be questioned; then if he further questioning reveals a lack of sufficient justification, its funding can be cut back or cancelled.
Remember also, this is the NIH we are talking about, so the audit spans a much larger scope than just Cancer Research. Remember somewhere else in the vast corridors at NIH an unelected bureaucrat is making Multi Million Dollar decisions to allocate Taxpayer funds to various programs. It is important that we root out any funding for research that has been outlawed. That sort of abuse not only is a waste of money, but also it is not compliant with US Policy.
It's not just grants either, contractors are a fertile area where abuse can languish for years when no one is looking. There are many areas that need to be looked at, leasing rental space that is not or seldom used for example. But your side doesn't even want to look, which puzzles me.
